The Central Drugs Standard Control Organization (CDSCO) will be soon issuing show cause notices to 29 firms and five traders who were found manufacturing and selling orthopedic implants without licences in recent raids.
According to a CDSCO official, these plants were found violating the norms under the Drugs and Cosmetics Act and Rules, 2018 in the selling and manufacturing of orthopedic implants.
"We are in the process of issuing show cause notices to these firms and traders and working on the details of the firms," the official said Saturday.
On March 11, inspectors at CDSCO conducted raids at 45 medical devices plants in four states, and found 29 of them and five traders manufacturing or selling orthopedic implants without licence or approval.
Further many of the units were using substandard material in unclean conditions, officials said.
Twenty-five firms were raided in the national capital, while searches were carried out in eight such facilities in Maharashtra, a senior official said, adding six firms each in Gujarat and Uttar Pradesh were also raided in a joint operation with officials of the states concerned.
"In the last two months, the CDSCO's intelligence cell gathered information from across the country regarding manufacture of various orthopedic implants without licences.
"It received information that a large number of unlicensed manufacturing activities were being carried out in Delhi, Uttar Pradesh, Gujarat and Maharashtra. Based on this information, the raids were carried out," the official said.
The intelligence cell at CDSCO was constituted in March, 2018. During raids, the officials found that the manufacturers did not hold valid licences and the devices were being made using substandard material in unclean conditions.
It was also found that the firms did not have quality management systems in place as is required under the Medical Devices Rules. Neither did the facilities conduct laboratory tests. Also they were just assembling the products and terming it as being manufactured by them, the official added.
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
